This report was first published by Endpoints News. To see the original version, click here
Biogen will pay as much as $1 billion — “predominantly” in milestone payments — to acquire a San Diego biotech that has disclosed little about its pipeline.
The startup, RayThera, debuted last year with a little more than $100 million in Series A funding from Foresite Capital and OrbiMed. It’s Biogen’s second acquisition this year so far.
您已阅读20%（429字），剩余80%（1689字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。